Letetresgene autoleucel clinical trials
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses letetresgene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
GlaxoSmithKline (4) · USWM CT, LLC (2) · USWM, LLC (dba US WorldMeds) (1)
Studies
Open first, then newest update. How each study uses letetresgene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell LiposarcomaCompletedPhase 2USWM, LLC (dba US WorldMeds)NCT05993299Written as Letetresgene autoleucel
- Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell LiposarcomaCompletedPhase 2USWM CT, LLCNCT06703346Written as Letetresgene autoleucel (Lete-Cel (GSK3377794))
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsActive, not recruitingPhase 2USWM CT, LLCNCT03967223Written as Letetresgene autoleucel (lete-cel, GSK3377794)
- Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell LiposarcomaCompletedPhase 2GlaxoSmithKlineNCT02992743Written as letetresgene autoleucel (GSK3377794)
- Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple MyelomaTerminatedPhase 1GlaxoSmithKlineNCT03168438Written as Letetresgene autoleucel
- Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1GlaxoSmithKlineNCT02588612Written as letetresgene autoleucel (GSK3377794)
- Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1aWithdrawnPhase 2GlaxoSmithKlineNCT03697824Written as GSK3377794
Codes
What other systems call letetresgene autoleucel · ClinicalTrials.gg INT016071
- UNII (FDA) B5ME4ZU4BSLETETRESGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C121379Letetresgene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B5ME4ZU4BS | LETETRESGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C121379 | Letetresgene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.